Corpus ID: 25567991

Gateways to clinical trials. December 2008.

@article{Tomillero2008GatewaysTC,
  title={Gateways to clinical trials. December 2008.},
  author={A. Tomillero and M. A. Moral},
  journal={Methods and findings in experimental and clinical pharmacology},
  year={2008},
  volume={30 10},
  pages={
          761-82
        }
}
  • A. Tomillero, M. A. Moral
  • Published 1 December 2008
  • Medicine
  • Methods and findings in experimental and clinical pharmacology
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a; Abatacept, ABT-263, Adalimumab, Aflibercept, Afobazole, Aliskiren fumarate, Anakinra, Atazanavir/ritonavir, Aviscumine… Expand
17 Citations
Prospects for future therapy of HCV infection
TLDR
The current status of drug development, ongoing clinical trials and future perspectives in the field of HCV therapeutics are reviewed. Expand
New therapeutic approaches to hepatitis C virus
TLDR
The current status of preclinical drug development, ongoing clinical trials, and near future perspectives in the field of HCV therapeutics are reviewed. Expand
Cancer Immunotherapy Confers a Global Benefit
TLDR
Cancer immunotherapy confers a global benefit and everybody all around the world has the right to benefit from this novel therapeutic avenue, which prevents further disabilities due to cancer progression or therapies and improves quality of life of patients. Expand
Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery
TLDR
These regimens provided an adequate antibacterial effect against the most common pathogens of biliary tract infections, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae with their MICs<2 mg/l. Expand
Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method
TLDR
A bioequivalence study was proved of generic Febuxostat 80 mg tablets (T) in healthy volunteers and a simple, sensitive, selective, rapid, rugged and reproducible liquid chromatography–tandem mass spectrometry method for the quantification of Febuxstat (FB) in human plasma using Febuxastat D7 (FBD7) as an internal standard (IS) was used. Expand
Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook
TLDR
Clinical and pharmacological data for nine recently approved targeted therapies, and considerations on how to use these new agents to treat non-AIDS-defining cancers, are presented. Expand
Small-molecule chromatin-modifying agents: therapeutic applications.
  • A. Mai
  • Biology, Medicine
  • Epigenomics
  • 2010
TLDR
The SIRT2-selective AGK-2 has been reported to have protective effects against Parkinson's disease, and resveratrol and other sirtuin activators can be useful for the treatment of Alzheimer's disease. Expand
Interactions of Enhanced Urocortin 2 and Mineralocorticoid Receptor Antagonism in Experimental Heart Failure
TLDR
A favorable profile of effects is demonstrated with short-term adjunct Ucn2 therapy and an MRA in HF, which further improved hemodynamics relative to that achieved by CA alone, while also reducing plasma renin activity, angiotensin II, aldosterone and vasopressin levels, and enhancing renal function. Expand
Prolonged Urocortin 2 Administration in Experimental Heart Failure: Sustained Hemodynamic, Endocrine, and Renal Effects
TLDR
4-day urocortin 2 administration induces sustained improvements in hemodynamics and renal function, in association with inhibition of multiple vasoconstrictor/volume-retaining systems, and these findings support the therapeutic potential for uroc Cortin 2 in heart failure. Expand
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
TLDR
Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs. Expand
...
1
2
...